Effect of powder inhaler design on drug deposition in the respiratory tract

Vidgrén, M.; Kärkkäinen, Anna‐Mari; Karjalainen, Panu; Paronen, Petteri; Nuutinen, Juhani

doi:10.1016/0378-5173(88)90177-9

Cited by 74 publications

(26 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Capsule-based DPIs can be limited by powder retention in the capsule and device, which leads to a reduction in the emitted dose (29). The drug retention could be minimised by coating the drug capsule and delivery device with pharmaceutically acceptable force-control agents (30).…”

Section: Resultsmentioning

confidence: 99%

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

et al. 2017

View full text Add to dashboard Cite

Abstract.Onbrez Breezhaler® is a low-resistance capsule-based device that was developed to deliver indacaterol maleate. The study was designed to investigate the effects of both maximum flow rate (MIF) and inhalation volume (Vin) on the dose emission of indacaterol 150 and 300 μg dose strengths after one and two inhalations using dose unit sampling apparatus (DUSA) as well as to study the aerodynamic characteristics of indacaterol Breezhaler® using the Andersen cascade impactor (ACI) at a different set of MIF and Vin. Indacaterol 150 and 300 μg contain equal amounts of lactose per carrier. However, 150 μg has the smallest carrier size. The particle size distribution (PSD) of indacaterol DPI formulations 150 and 300 μg showed that the density of fine particles increased with the increase of the primary pressure. For both strengths (150 μg and 300 μg), ED1 increased and ED2 decreased when the inhalation flow rate and inhaled volume increased. The reduction in ED1 and subsequent increase in ED2 was such that when the Vin is greater than 1 L, then 60 L/min could be regarded as the minimum MIF. The Breezhaler was effective in producing respirable particles with an MMAD ≤5 μm irrespective of the inhalation flow rate, but the mass fraction of particles with an aerodynamic diameter <3 μm is more pronounced between 60 and 90 L/min. The dose emission of indacaterol was comparable for both dose strengths 150 and 300 μg. These in vitro results suggest that a minimum MIF of 60 L/min is required during routine use of Onbrez Breezhaler®, and confirm the good practice to make two separate inhalations from the same dose.

show abstract

Section: Resultsmentioning

confidence: 99%

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Thus, values for Spinhaler® have been reported to be 12% [18], and for Rotahaler® and Diskhaler® values of about 10% have been reported [19,20,21].…”

Section: Discussionmentioning

confidence: 99%

Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects

Borgström¹,

Bondesson²,

Morén³

et al. 1994

Eur Respir J

257

118

View full text Add to dashboard Cite

We wanted to evaluate whether lung deposition of budesonide and terbutaline sulphate differs, and to determine lung deposition of budesonide inhaled at different peak inspiratory flows, through Turbuhaler. Lung deposition of budesonide, a lipophilic substance, and of terbutaline sulphate, a hydrophilic substance, was therefore compared, after administration via an inspiratory flow-driven, multi-dose, powder inhaler (Turbuhaler, Astra Draco AB) to 10 healthy volunteers. The radionuclide 99mTc was used to label drug particles, and radioactivity, indicating drug deposition, was measured using a gamma camera. Budesonide was inhaled at a normal flow of 58 l.min-1 and at a slow flow of 36 l-min-1. At the faster flow, a mean +/- SD 27.7 +/- 9.5% of the metered dose was deposited in the lung and at the slower flow 14.8 +/- 3.3% was deposited (p < 0.001). Mean lung deposition of terbutaline sulphate inhaled at 57 l.min-1 was 27.0 +/- 7.7%. We conclude that inspiratory flow has an important effect on lung deposition, but water solubility appears to have no effect.

show abstract

“…A deposição pulmonar de partículas varia com o tipo de inalador de pó 10,85 , com o fluxo inspiratório 10 utilizado e com a presença ou não de obstrução brônquica (Tabela 5). A inalação de aerossol gerado por inalador de pó se acompanha de uma significativa deposição de partículas na orofaringe: com o Turbuhaler, cerca de 57% depositam-se na orofaringe 18 e perdem-se na peça bucal em torno de 24% do aerossol gerado 18 , enquanto que, em média, 17% são depositados nos pulmões e 2% retornam com o ar expirado 18 .…”

Section: Aerossolterapia Na Asma Da Criança -Souza Lsfunclassified

Aerosol therapy in childhood asthma

Souza

1998

J Pediatr (Rio J)

View full text Add to dashboard Cite

IntroduçãoA ligação direta do aparelho respiratório com o meio ambiente faculta a administração de medicamentos às vias aéreas inferiores, através do ar inspirado. Indiscutivelmente, a asma é a doença em que mais se utiliza a via inalatória, tanto no tratamento da crise, como no tratamento profiláti-co. Os bons resultados no tratamento da asma têm justificado a extensa pesquisa que vem sendo realizada no sentido de desenvolver novas e melhores drogas para uso inalató-rio e de aprimorar o modo de administração e os dispositivos inalatórios.Os atrativos da via inalatória no tratamento da asma são os seguintes:• efeitos quase imediatos, devidos à rapidez com que os medicamentos chegam ao local de ação (interessante no tratamento da crise); • efeitos terapêuticos plenos, conseguidos com pequenas doses (interessante no tratamento da crise e no tratamento profilático); • raridade de efeitos colaterais (o que proporciona segurança ao tratamento profilático e também ao tratamento da crise).Quase todos os broncodilatadores, diversos corticosteróides e outras drogas profiláticas, como o Cromoglicato Dissódico e o Nedocromil, são disponíveis em apresentações para uso inalatório. ResumoObjetivos: Os objetivos dessa revisão são apresentar resultados de pesquisas em aerossolterapia e discutir a otimização dessa forma de administração de medicamentos.Método: Foram revistos alguns dos principais trabalhos publicados sobre aerossolterapia, sobre aparelhos geradores de aerossol, e sobre farmacocinética e farmacodinâmica das drogas inaladas.Resultados: São apresentados os fatores que interferem sobre o padrão de deposição das drogas inaladas, sua farmacocinética e a influência da deposição e da farmacocinética sobre os efeitos do tratamento. Os aparelhos geradores de aerossol são comparados, em seus aspectos positivos e negativos, e procura-se estabelecer equivalência entre doses com diferentes dispositivos inalatórios.Conclusões: Os aparelhos geradores de aerossol e as técnicas inalatórias determinam o padrão de deposição e os efeitos clínicos das drogas. Esses fatores devem ser bem conhecidos, a fim de se alcançarem os melhores resultados possíveis no tratamento por via inalatória.J. pediatr. (Rio J.). 1998; 74(3):189-204: aerossol, técnicas inalatórias, deposição de partículas, farmacocinética, aparelhos geradores de aerossol. AbstractObjectives: The aims of this review are to present research data about aerosoltherapy and to discuss the optimization of this form of drug administration.Method: Review of the literature, covering some of the most important studies about aerosoltherapy, inhaler devices, pharmacokinetics and pharmacodynamics of inhaled drugs.Results: Factors that influence deposition pattern and pharmacokinetics of inhaled drugs are discussed, as well as how they can affect clinical efficacy. Positive and negative features of inhaler devices are compared; an attempt to establish dose equivalency of drug delivered by different devices is made.Conclusions: Different inhaler devices and different inhaling techniques ...

show abstract

Effect of powder inhaler design on drug deposition in the respiratory tract

Cited by 74 publications

References 9 publications

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects

Aerosol therapy in childhood asthma

Contact Info

Product

Resources

About